Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
WTX212A
- Development stage
- Phase 1
- Lead developer
- Westlake Therapeutics
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
WTX212A is an antibody-cell conjugate (ACC) consisting of an anti-PD-1 monoclonal antibody conjugated to erythrocytes (red blood cells). It is being developed by Westlake Therapeutics for the treatment of advanced solid tumors and hematologic malignancies. The drug acts as a PD-1 inhibitor—blocking the programmed cell death protein 1 (PD-1) pathway to enhance immune responses against cancer cells. Clinical trials are ongoing in early phase 1 for patients with unresectable or metastatic advanced solid tumors who have failed previous systemic therapies[1][5][8].
- Other names
- engineered red blood cellerythrocyte-anti-PD1 antibody conjugateerythrocyte-anti-PD-1 antibody conjugateerythrocyte-anti-PD 1 antibody conjugateerythrocyte-αPD-1 conjugate
02
Targets
PDCD1 (Programmed cell death protein 1 receptor)
Beyond the preview
Go deeper on WTX212A.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on WTX212A.